• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在转移性结直肠癌患者中，高RBM3表达与生存期改善及奥沙利铂反应相关。

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.

作者信息

Siesing Christina, Sorbye Halfdan, Dragomir Anca, Pfeiffer Per, Qvortrup Camilla, Pontén Fredrik, Jirström Karin, Glimelius Bengt, Eberhard Jakob

机构信息

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Skåne University Hospital, Lund, Sweden.

Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway.

出版信息

PLoS One. 2017 Aug 11;12(8):e0182512. doi: 10.1371/journal.pone.0182512. eCollection 2017.

DOI:10.1371/journal.pone.0182512
PMID:28800641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5553773/
Abstract

BACKGROUND

High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in metastatic colorectal cancer (mCRC) as a prognostic factor for overall survival and in relation to benefit of first-line chemotherapy.

METHODS

Immunohistochemical staining was conducted and evaluated in tumours from 455 mCRC patients. Kaplan-Meier analysis and Cox regression proportional hazards models were used to access the impact of RBM3 expression on overall survival (OS) and progression-free survival (PFS).

RESULTS

High RBM3 expression, both nuclear and cytoplasmic, was an independent prognostic factor for prolonged OS (hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.50-0.90 and HR 0.66, 95% CI 0.48-0.91, respectively). PFS was significantly longer in patients with high RBM3 expression who had received first-line oxaliplatin based treatment, compared to those who had received irinotecan based treatment, both regarding nuclear and cytoplasmic expression (p-value 0.020 and 0.022 respectively).

CONCLUSION

High RBM3 expression is an independent predictor of prolonged survival in mCRC patients, in particular in patients treated with first-line oxaliplatin based chemotherapy.

摘要

背景

RNA结合基序蛋白3（RBM3）的高表达已被证明与几种恶性疾病的生存期延长以及卵巢癌中铂类化疗的获益相关。本研究的目的是评估转移性结直肠癌（mCRC）中RBM3作为总生存期的预后因素以及与一线化疗获益的关系。

方法

对455例mCRC患者的肿瘤进行免疫组织化学染色并评估。采用Kaplan-Meier分析和Cox回归比例风险模型来评估RBM3表达对总生存期（OS）和无进展生存期（PFS）的影响。

结果

RBM3的核表达和胞质表达均为OS延长的独立预后因素（风险比[HR]分别为0.67，95%置信区间[CI] 0.50 - 0.90和HR 0.66，95% CI 0.48 - 0.91）。在接受一线奥沙利铂治疗的高RBM3表达患者中，无论是核表达还是胞质表达，其PFS均显著长于接受伊立替康治疗的患者（p值分别为0.020和0.022）。

结论

RBM3高表达是mCRC患者生存期延长的独立预测因素，尤其是在接受一线奥沙利铂化疗的患者中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cea/5553773/ec61be310c88/pone.0182512.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cea/5553773/e0b63f0abf9f/pone.0182512.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cea/5553773/579a32bf4833/pone.0182512.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cea/5553773/ec61be310c88/pone.0182512.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cea/5553773/e0b63f0abf9f/pone.0182512.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cea/5553773/579a32bf4833/pone.0182512.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cea/5553773/ec61be310c88/pone.0182512.g003.jpg

相似文献

1
High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.在转移性结直肠癌患者中，高RBM3表达与生存期改善及奥沙利铂反应相关。
PLoS One. 2017 Aug 11;12(8):e0182512. doi: 10.1371/journal.pone.0182512. eCollection 2017.
2
Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.RNA 结合基序蛋白 3 的表达降低与膀胱癌的肿瘤进展和不良预后相关。
BMC Urol. 2013 Apr 8;13:17. doi: 10.1186/1471-2490-13-17.
3
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).西地尼布联合 FOLFOX/CAPOX 对比安慰剂联合 FOLFOX/CAPOX 一线治疗转移性结直肠癌的随机、双盲、III 期临床研究（HORIZON II）
J Clin Oncol. 2012 Oct 10;30(29):3596-603. doi: 10.1200/JCO.2012.42.6031. Epub 2012 Sep 10.
4
Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer.低RBM3蛋白表达与睾丸非精原细胞性生殖细胞癌的临床分期、预后分类及治疗失败风险增加相关。
PLoS One. 2015 Mar 26;10(3):e0121300. doi: 10.1371/journal.pone.0121300. eCollection 2015.
5
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).表皮调节素和双调蛋白的mRNA表达对接受5-氟尿嘧啶/亚叶酸钙联合伊立替康或伊立替康联合奥沙利铂作为一线治疗的转移性结直肠癌患者预后的影响（FIRE 1试验）
Int J Cancer. 2016 Feb 1;138(3):739-46. doi: 10.1002/ijc.29807. Epub 2015 Sep 18.
6
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).西地尼布联合 mFOLFOX6 对比贝伐珠单抗联合 mFOLFOX6 一线治疗晚期结直肠癌的双盲、随机 III 期研究（HORIZON III）。
J Clin Oncol. 2012 Oct 10;30(29):3588-95. doi: 10.1200/JCO.2012.42.5355. Epub 2012 Sep 10.
7
High RNA-Binding Motif Protein 3 (RBM3) Expression is Independently Associated with Prolonged Overall Survival in Intestinal-Type Gastric Cancer.高 RNA 结合基序蛋白 3（RBM3）表达与肠型胃癌的总生存时间延长独立相关。
Med Sci Monit. 2017 Dec 21;23:6033-6041. doi: 10.12659/msm.905314.
8
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.随机、III 期临床试验：帕尼单抗联合氟尿嘧啶、亚叶酸钙和奥沙利铂（FOLFOX4）对比 FOLFOX4 一线治疗未经治疗的转移性结直肠癌患者：PRIME 研究。
J Clin Oncol. 2010 Nov 1;28(31):4697-705. doi: 10.1200/JCO.2009.27.4860. Epub 2010 Oct 4.
9
Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study.低 RBM3 蛋白表达与恶性黑色素瘤的肿瘤进展和不良预后相关：来自马尔默饮食与癌症研究的 215 例病例分析。
J Transl Med. 2011 Jul 21;9:114. doi: 10.1186/1479-5876-9-114.
10
High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer.核 RBM3 高表达与结直肠癌预后改善相关。
Proteomics Clin Appl. 2011 Dec;5(11-12):624-35. doi: 10.1002/prca.201100020.

引用本文的文献

1
Prognostic Significance of RBM3 Expression in Epithelial Ovarian Cancer: A Tissue Microarray-Based Study.RBM3表达在上皮性卵巢癌中的预后意义：一项基于组织芯片的研究。
Diagnostics (Basel). 2025 Jun 3;15(11):1426. doi: 10.3390/diagnostics15111426.
2
The 3-Biomarker Classifier-A Novel and Simple Molecular Risk Score Predicting Overall Survival in Patients with Colorectal Cancer.三生物标志物分类器——一种预测结直肠癌患者总生存期的新型简单分子风险评分
Cancers (Basel). 2024 Sep 22;16(18):3223. doi: 10.3390/cancers16183223.
3
RNA binding proteins (RBPs) and their role in DNA damage and radiation response in cancer.

本文引用的文献

1
Expression of RNA-binding Motif Protein 3 () and Cold-inducible RNA-binding protein () Is Associated with Improved Clinical Outcome in Patients with Colon Cancer.RNA结合基序蛋白3（RBM3）和冷诱导RNA结合蛋白（CIRBP）的表达与结肠癌患者临床预后改善相关。
Anticancer Res. 2017 Apr;37(4):1779-1785. doi: 10.21873/anticanres.11511.
2
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.FOLFOXIRI 联合贝伐珠单抗对比 FOLFIRI 联合贝伐珠单抗一线治疗转移性结直肠癌患者：开放标签、3 期 TRIBE 研究的总生存更新及分子亚组分析。
Lancet Oncol. 2015 Oct;16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31.
3
RNA 结合蛋白（RBPs）及其在癌症中 DNA 损伤和辐射反应中的作用。
Adv Drug Deliv Rev. 2022 Dec;191:114569. doi: 10.1016/j.addr.2022.114569. Epub 2022 Oct 14.
4
Delineating the intra-patient heterogeneity of molecular alterations in treatment-naïve colorectal cancer with peritoneal carcinomatosis.在未经治疗的伴有腹膜转移的结直肠癌中描绘分子改变的患者内异质性。
Mod Pathol. 2022 Jul;35(7):979-988. doi: 10.1038/s41379-022-01012-y. Epub 2022 Feb 15.
5
Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.RBM3 在肌层浸润性膀胱癌中的作用的临床前和临床研究：纵向表达、转录组水平的影响和化疗敏感性的调节。
BMC Cancer. 2022 Feb 2;22(1):131. doi: 10.1186/s12885-021-09168-7.
6
The RNA-Binding Motif Protein Family in Cancer: Friend or Foe?癌症中的RNA结合基序蛋白家族：是友还是敌？
Front Oncol. 2021 Nov 4;11:757135. doi: 10.3389/fonc.2021.757135. eCollection 2021.
7
Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.系统分析卵巢癌预后与可变剪接的关系。
J Ovarian Res. 2021 Sep 15;14(1):120. doi: 10.1186/s13048-021-00866-1.
8
Cold stress protein RBM3 responds to hypothermia and is associated with good stroke outcome.冷应激蛋白RBM3对体温过低作出反应，并与中风的良好预后相关。
Brain Commun. 2020 Jun 4;2(2):fcaa078. doi: 10.1093/braincomms/fcaa078. eCollection 2020.
9
Long Noncoding RNA AFAP1-AS1 Is a Critical Regulator of Nasopharyngeal Carcinoma Tumorigenicity.长链非编码RNA AFAP1-AS1是鼻咽癌致瘤性的关键调节因子。
Front Oncol. 2020 Nov 23;10:601055. doi: 10.3389/fonc.2020.601055. eCollection 2020.
10
Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non-small cell lung cancer.RNA 结合基序蛋白 3（RBM3）在非小细胞肺癌中的综合分析。
Cancer Med. 2020 Aug;9(15):5609-5619. doi: 10.1002/cam4.3149. Epub 2020 Jun 3.
High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.在一项基于人群的前瞻性转移性结直肠癌队列中，根据KRAS/BRAF突变状态和肿瘤组织可获得性，BRAF突变频率较高，且亚组间存在显著的生存差异。
PLoS One. 2015 Jun 29;10(6):e0131046. doi: 10.1371/journal.pone.0131046. eCollection 2015.
4
Loss of RNA-binding motif protein 3 expression is associated with right-sided localization and poor prognosis in colorectal cancer.RNA结合基序蛋白3表达缺失与结直肠癌的右侧定位及不良预后相关。
Histopathology. 2016 Jan;68(2):191-8. doi: 10.1111/his.12726. Epub 2015 Jul 22.
5
Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer.低RBM3蛋白表达与睾丸非精原细胞性生殖细胞癌的临床分期、预后分类及治疗失败风险增加相关。
PLoS One. 2015 Mar 26;10(3):e0121300. doi: 10.1371/journal.pone.0121300. eCollection 2015.
6
Global cancer statistics, 2012.全球癌症统计数据，2012 年。
CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.
7
Proteomics. Tissue-based map of the human proteome.蛋白质组学。人类蛋白质组组织图谱。
Science. 2015 Jan 23;347(6220):1260419. doi: 10.1126/science.1260419.
8
Cancer statistics, 2015.癌症统计数据，2015 年。
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
9
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.FOLFIRI 联合西妥昔单抗与 FOLFIRI 联合贝伐珠单抗一线治疗转移性结直肠癌患者（FIRE-3）：一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31.
10
High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death.RNA 结合基序蛋白 3 在食管和胃腺癌中的高表达与肠上皮化生相关肿瘤相关，并独立预测复发和死亡风险降低。
Biomark Res. 2014 Jun 17;2:11. doi: 10.1186/2050-7771-2-11. eCollection 2014.